India’s hospital IPOs have been building momentum for a few years now, but nothing quite on this scale has come along yet. Manipal Health Enterprises — the operator behind one of the country’s largest hospital networks — is preparing a public listing that industry watchers are already calling the biggest healthcare IPO India has ever seen, with talk of a valuation that would push past $12 billion.
That’s a big claim, and it deserves a proper look rather than just repeating the headline number. Between the fresh issue size, the Temasek-backed Offer for Sale, and a set of financial figures that genuinely don’t agree with each other across different sources, there’s a lot to unpack here before you decide how much attention this IPO deserves on your watchlist.
Here’s everything currently known about Manipal Health’s IPO, its business, and the details worth double-checking before the official price band lands.
Who Is Manipal Health Enterprises Limited?
Manipal Health Enterprises is part of the broader Manipal Group, an institution originally founded by T. M. A. Pai that’s built a long-standing reputation across both healthcare and education in India. The hospital arm has grown into what’s now described as India’s largest pan-India multispecialty hospital network by bed capacity — a genuinely significant claim in a country with no shortage of large, well-funded hospital chains.
The company runs a wide-ranging portfolio of healthcare services, spanning tertiary and quaternary care, organ transplants, oncology, cardiology, neurology, orthopaedics, and preventive health programs. As of September 30, 2025, Manipal Health operated 38 hospitals, or 48 hospitals when counted on a pro forma basis that presumably includes recently acquired or soon-to-be-consolidated facilities, with 10,761 licensed beds — 12,367 on that same pro forma basis.
The “CONGO-R” Specialty Focus
One detail that stands out in Manipal Health’s business model is its deliberate concentration on what the company internally refers to as “CONGO-R” specialties — Cardiac, Oncology, Neuro, Gastro, Ortho, and Renal sciences. These are consistently among the highest-value, highest-margin specialties in hospital care, and a significant share of the company’s revenue is reportedly generated from this cluster.
This kind of specialty concentration isn’t accidental. Complex tertiary and quaternary procedures in these six areas tend to command premium pricing, require advanced equipment and specialist talent that smaller hospitals can’t easily replicate, and build the kind of clinical reputation that keeps patients coming back to a specific network rather than shopping around. It’s a strategy that mirrors what several of India’s other large listed hospital chains have pursued as well.
Growth Through Acquisition and Investment
Manipal Health has expanded its footprint through a mix of strategic acquisitions, partnerships, and continuous investment in medical infrastructure, rather than relying purely on building new hospitals from the ground up. The gap between its 38 operational hospitals and the 48 counted on a pro forma basis suggests the company has recent or pending acquisitions still working their way into full consolidation — a detail worth watching for more clarity once the RHP is public.
Manipal Health Enterprises IPO: Key Details
| Detail | Information |
|---|---|
| IPO Type | Mainboard, 100% Book Build Issue |
| DRHP Filed | March 23, 2026 |
| SEBI Approval | Granted July 3, 2026 |
| Fresh Issue | Up to ₹8,000 crore |
| Offer for Sale (OFS) | Up to 4,32,27,668 equity shares (~4.32 crore shares) |
| Face Value | ₹2 per share |
| Price Band | Not yet officially confirmed |
| Lot Size | Not yet announced |
| Listing Exchanges | BSE, NSE |
| Registrar | KFin Technologies Ltd. |
| Lead Manager | Kotak Mahindra Capital Co. Ltd. |
| Reservation | QIB 50%, Retail 35%, NII 15% |
A note on the dates you may have seen circulating: Some IPO tracking platforms have published specific opening, closing, and listing dates for this issue — late July into early August 2026 — while showing the price band and lot size as blank on the very same page. That kind of mismatch usually means the dates are provisional or auto-populated rather than officially confirmed by the company. Given the scale of this IPO and the fact that the price band hasn’t been locked in yet, it’s worth treating any specific date you’ve seen as tentative until Manipal Health files its RHP with confirmed pricing.
A Sizeable Fresh Issue, Backed by a Marquee OFS Seller
The fresh issue portion of ₹8,000 crore is genuinely large by Indian IPO standards, and it signals the company intends to use a meaningful chunk of this listing to fund its own growth rather than simply providing an exit route for existing shareholders. Alongside that, the Offer for Sale of roughly 4.32 crore shares is reportedly being led by Temasek, the Singapore state investment firm, among other existing shareholders looking to monetize part of their stake.
Temasek’s involvement is worth noting on its own. Sovereign wealth funds and large global institutional investors don’t typically take positions in private healthcare companies without extensive due diligence, and their participation as a selling shareholder in the IPO — rather than a full exit — often suggests continued confidence in the company’s prospects even as they partially monetize their existing investment.
Promoter and Ownership Structure
Manipal Health Enterprises is led by promoters including Dr. Ranjan Ramdas Pai, along with several Manipal-affiliated and associated investment entities. Before the IPO, promoters collectively held above 90% of the company. Post-listing, that stake will be diluted as a result of both the fresh issue and the OFS component. Dr. Hebri Sudarshan Ballal serves as Chairman, providing overall strategic direction for the group.
Financial Performance: A Genuine Discrepancy Worth Flagging
This is the part of the story that deserves the most careful reading, because the numbers simply don’t match across different sources currently reporting on this IPO — and pretending otherwise wouldn’t serve you well.
Two Very Different Sets of Figures
One set of figures, tied to fiscal year 2025, reports revenue from operations of ₹8,242.25 crore and a Profit After Tax of ₹1,081.67 crore. A separate source, also referencing 2025, cites revenue of ₹9,409.12 crore but a considerably lower PAT of ₹534.80 crore.
Neither the revenue nor the profit figures line up between these two sets of numbers, and the gap isn’t small — PAT differs by more than double depending on which figure you look at. This kind of discrepancy typically comes down to one of a few possibilities: differences between standalone and consolidated financials, differences between actual reported figures and pro forma figures that account for recent acquisitions, or simply different reporting periods being labeled the same way by different platforms.
The honest takeaway: Until Manipal Health’s audited financials are available directly through the RHP, treat both sets of numbers as provisional. What’s consistent across sources is that this is a large, revenue-generating business with genuine profitability — the exact scale of that profitability is the detail worth confirming once official documents are public.
Debt Levels Worth Watching
As of January 31, 2026, the company’s aggregate outstanding borrowings on a consolidated basis stood at approximately ₹10,612.78 crore. That’s a substantial debt load, and it’s worth keeping in mind alongside the ₹8,000 crore fresh issue — a portion of those proceeds may well be directed toward deleveraging, though the exact use-of-proceeds breakdown will only become clear once the RHP specifies it. A hospital network carrying this much debt while simultaneously funding acquisitions and infrastructure investment is not unusual for the sector, but it’s a detail that directly affects how much of the fresh capital actually goes toward growth versus balance sheet repair.
The Valuation Story: Could This Be India’s Most Valuable Hospital Operator?
Reports around this IPO have pointed to a targeted valuation of roughly $12 billion, or approximately ₹1,00,000 crore. If Manipal Health lists anywhere close to that figure, it would leapfrog Max Healthcare — currently one of India’s most valuable listed hospital chains, with a market capitalization of around ₹94,053 crore — to become the country’s most valuable listed hospital operator.
For context, investors evaluating whether that kind of valuation is justified would typically benchmark Manipal Health against a basket of listed peers, including Apollo Hospitals, Max Healthcare, Fortis Healthcare, and Global Health (which operates as Medanta). Each of these companies commands a premium valuation multiple relative to traditional industrial or manufacturing businesses, largely because hospital chains combine steady, recurring demand with high barriers to entry — building a new large-format multispecialty hospital and staffing it with specialist talent takes years, not months.
Whether Manipal Health’s targeted valuation holds up will ultimately depend on how its actual, confirmed financials compare to these listed peers on standard metrics like revenue per bed, EBITDA margins, and occupancy rates — none of which can be properly assessed until the RHP resolves the financial discrepancies currently circulating.
Strengths Worth Noting
- Scale leadership. Being described as India’s largest pan-India multispecialty hospital network by bed capacity is a genuinely strong competitive position in a fragmented industry.
- High-value specialty focus. The CONGO-R specialty concentration targets exactly the kind of complex, high-margin care that builds both profitability and clinical reputation.
- Marquee institutional backing. Temasek’s involvement as a lead OFS seller lends credibility, and their continued partial ownership post-IPO suggests sustained confidence in the business.
- Substantial fresh capital. An ₹8,000 crore fresh issue gives the company meaningful firepower for further expansion, debt reduction, or both, depending on the final use-of-proceeds breakdown.
- Established brand and heritage. Being part of the long-standing Manipal Group brings decades of institutional credibility in both healthcare and education sectors.
- Active expansion pipeline. The gap between current operational hospitals (38) and the pro forma count (48) suggests continued growth through acquisitions already in motion.
Risks and Concerns to Keep in Mind
- Conflicting financial figures. The meaningful gap between different reported revenue and PAT figures for the same fiscal year is a genuine red flag worth resolving before forming any valuation opinion.
- Substantial debt load. Over ₹10,600 crore in consolidated borrowings is a significant liability that could constrain financial flexibility if not addressed through IPO proceeds or improved cash flow generation.
- Unconfirmed price band and dates. Despite specific-looking dates circulating on some platforms, the actual price band and lot size remain undeclared, and investors should treat any current date as provisional.
- Ambitious valuation target. A $12 billion target valuation is a significant ask, and it will draw close scrutiny against listed peers once real financials are available — there’s real execution risk in the market simply not agreeing with that price tag.
- Heavy promoter concentration. At over 90% pre-IPO ownership, governance structures and related-party arrangements are worth reviewing carefully once fully disclosed in the RHP.
- Sector-wide regulatory exposure. Hospital chains in India operate under evolving healthcare regulation, insurance reimbursement policies, and periodic government pricing interventions on certain procedures and devices, all of which can affect margins.
- Integration risk from acquisitions. Growth partly driven by acquisitions carries execution risk — integrating newly acquired hospitals into a consistent quality and operational standard takes time and can strain margins during the transition.
How Manipal Health Compares to Listed Hospital Peers
India’s listed hospital sector already includes several well-established names that Manipal Health will inevitably be compared against. Apollo Hospitals remains one of the oldest and most diversified players, spanning hospitals, pharmacies, and digital health. Max Healthcare has built a strong presence in the National Capital Region and beyond, with a market capitalization currently around ₹94,053 crore. Fortis Healthcare operates a similarly broad multispecialty network, while Global Health, operating under the Medanta brand, has built a reputation specifically around complex tertiary care.
Manipal Health’s pitch to investors will likely center on its combination of scale — the largest bed capacity in the country — and its specialty-driven revenue mix through the CONGO-R focus areas. Whether that combination justifies a valuation that would make it India’s single most valuable listed hospital operator is the central question the market will answer once trading begins.
What to Watch For Before the Official Launch
- Official confirmation of the price band and lot size through the RHP
- Resolution of the conflicting revenue and PAT figures currently circulating across different sources
- Clarity on how much of the ₹8,000 crore fresh issue will go toward debt reduction versus new capital expenditure and acquisitions
- Confirmed opening, closing, and listing dates once officially announced by the company
- How the market prices Manipal Health relative to Apollo Hospitals, Max Healthcare, Fortis Healthcare, and Global Health once real financials and valuation multiples are available for comparison
How to Apply Once the IPO Opens
- Log into your broker’s platform or your bank’s net banking portal.
- Navigate to the IPO section and locate the Manipal Health Enterprises listing once subscription opens.
- Choose ASBA through net banking, or the UPI mandate route through your broker.
- Enter your bid quantity and price once the official price band is confirmed.
- Submit the application and approve the UPI mandate through your banking app before the cut-off time.
As with any book-built mainboard IPO, your funds get blocked rather than debited immediately, and are released automatically if you don’t receive an allotment.
Frequently Asked Questions
- When will the Manipal Health Enterprises IPO open?
Exact dates remain officially unconfirmed as of this writing. Some trackers have shown late July to early August 2026 as a tentative window, but the price band and final schedule are still pending official announcement.
- What is the price band for the Manipal Health IPO?
The price band has not been officially declared yet. It will be disclosed in the Red Herring Prospectus (RHP) closer to the actual launch.
- How big is the Manipal Health Enterprises IPO?
The issue combines a fresh issue of up to ₹8,000 crore with an Offer for Sale of roughly 4.32 crore equity shares. The exact total issue size in rupee terms will be confirmed once the price band is announced.
- What valuation is Manipal Health targeting?
Reports suggest a targeted valuation of roughly $12 billion (approximately ₹1,00,000 crore), which would make it India’s most valuable listed hospital operator if achieved.
- How many hospitals does Manipal Health operate?
As of September 30, 2025, the company operated 38 hospitals, or 48 on a pro forma basis, with 10,761 licensed beds (12,367 on a pro forma basis).
- What is Manipal Health’s revenue and profit?
Reported figures vary across sources — one cites FY25 revenue of ₹8,242.25 crore and PAT of ₹1,081.67 crore, while another reports revenue of ₹9,409.12 crore and PAT of ₹534.80 crore for the same year. This discrepancy should be resolved once official audited financials are available in the RHP.
- Who are the promoters of Manipal Health Enterprises?
Dr. Ranjan Ramdas Pai leads the promoter group, along with Manipal Group-affiliated entities, collectively holding more than 90% of the company before the IPO. Dr. Hebri Sudarshan Ballal serves as Chairman.
- Who is managing the IPO?
Kotak Mahindra Capital Co. Ltd. is the lead manager, with KFin Technologies Ltd. serving as registrar.
Final Thoughts: Worth the Hype?
Manipal Health Enterprises is shaping up to be one of the most closely watched IPOs of the year, and there’s genuine substance behind the attention — a nationally dominant hospital network, a high-margin specialty focus, and backing from a globally respected institutional investor in Temasek. If the company lists anywhere near its reported $12 billion target, it would mark a genuine milestone for India’s healthcare sector as a whole.
At the same time, the conflicting financial figures currently circulating are not a detail to wave away. A gap of this size between reported revenue and profit numbers needs a clear answer before any investor can reasonably judge whether the eventual valuation makes sense. Layer on top of that a meaningful debt load and a price band that’s still undeclared, and the responsible approach here is patience rather than premature enthusiasm.
Keep Manipal Health on your radar, but hold off on forming a firm view until the RHP resolves the numbers that matter most — audited financials, a locked price band, and a clear picture of how the ₹8,000 crore fresh issue will actually be deployed. Once those are public, you’ll be in a genuinely informed position to judge whether this IPO lives up to its billing as India’s biggest healthcare listing yet.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO investments are subject to market risk. Details mentioned here reflect publicly available information at the time of writing, which includes some inconsistencies across sources, and are subject to change once the company officially announces its price band and IPO dates. Please consult a SEBI-registered investment advisor and read the official RHP before applying.